Microbix Biosystems's revenue for the
three
months ended in Mar. 2026 was $2.46 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $10.77 Mil.
Microbix Biosystems's Revenue per Share for the
three
months ended in Mar. 2026 was $0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08.
Warning Sign:
Microbix Biosystems Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Microbix Biosystems was -35.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Microbix Biosystems's highest 3-Year average Revenue per Share Growth Rate was 21.60% per year. The lowest was -14.70% per year. And the median was 1.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Microbix Biosystems Revenue Related Terms
Microbix Biosystems Revenue Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Microbix Biosystems's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Revenue distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (MBXBF) has a Revenue of $10.77 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Revenue too high?
Microbix Biosystems' current Revenue is $10.77 Mil. Overall, Microbix Biosystems has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Revenue compare to VRTX and REGN?
Microbix Biosystems' Revenue of $10.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Revenue is $10.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.22 — trading 26.5% above its estimated fair value. The current Revenue is $10.77 Mil. Microbix Biosystems' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Revenue is $10.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 26.5% above its estimated GF Value™ of $0.17.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
Revenue: $10.77 Mil
GF Value™: $0.17 vs. price of $0.22 (26.5% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
51GF Score
Get the complete analysis for MBXBF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
